{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:54:15Z","timestamp":1782168855496,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.cmi.2020.05.016","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:40:47Z","timestamp":1590493247000},"page":"979-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review"],"prefix":"10.1016","volume":"26","author":[{"given":"C.","family":"Rodrigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rajapakse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.05.016_bib1","first-page":"288","article-title":"Treatment of viral hepatitis with chloroquine","volume":"39","author":"Pareja-Coronel","year":"1963","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2020.05.016_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In\u00a0vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cmi.2020.05.016_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.cmi.2020.05.016_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/14787210.4.2.291","article-title":"Potential antivirals and antiviral strategies against SARS coronavirus infections","volume":"4","author":"De Clercq","year":"2006","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.cmi.2020.05.016_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.cmi.2020.05.016_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.016_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.016_bib8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jmv.25440","article-title":"Antimalarial drugs and their metabolites are potent Zika virus inhibitors","volume":"91","author":"Han","year":"2019","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2020.05.016_bib9","doi-asserted-by":"crossref","first-page":"18132","DOI":"10.1021\/acsomega.8b01002","article-title":"Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease","volume":"3","author":"Kumar","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.cmi.2020.05.016_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15467-6","article-title":"Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis","volume":"7","author":"Shiryaev","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2020.05.016_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cbf.3182","article-title":"Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity","volume":"34","author":"Akpovwa","year":"2016","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.cmi.2020.05.016_bib12","article-title":"Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry","volume":"4","author":"Barclay","year":"2015","journal-title":"F1000 Res"},{"key":"10.1016\/j.cmi.2020.05.016_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.coviro.2012.02.016","article-title":"Henipavirus outbreaks to antivirals: the current status of potential therapeutics","volume":"2","author":"Broder","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cmi.2020.05.016_bib14","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2020.05.016_bib15","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2020.05.016_bib16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2020.05.016_bib17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0149-2918(95)80039-5","article-title":"Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1","volume":"17","author":"Sperber","year":"1995","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2020.05.016_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0149-2918(97)80045-8","article-title":"Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1","volume":"19","author":"Sperber","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2020.05.016_bib19","first-page":"1229","article-title":"Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children","volume":"89","author":"Engchanil","year":"2006","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.cmi.2020.05.016_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2012.6936","article-title":"Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial","volume":"308","author":"Paton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.05.016_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1089\/aid.2015.0336","article-title":"The effect of chloroquine on immune activation and interferon signatures associated with HIV-1","volume":"32","author":"Jacobson","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cmi.2020.05.016_bib22","doi-asserted-by":"crossref","first-page":"12082","DOI":"10.1128\/JVI.01466-10","article-title":"Reduction of immune activation with chloroquine therapy during chronic HIV infection","volume":"84","author":"Murray","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2020.05.016_bib23","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2011-01-329060","article-title":"Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders","volume":"118","author":"Piconi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2020.05.016_bib24","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(02)08557-4","article-title":"Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1","volume":"359","author":"Paton","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.05.016_bib25","first-page":"46","article-title":"Effect of chloroquine on some clinical and biochemical parameters in non-response chronic hepatitis C virus infection patients: pilot clinical trial","volume":"87","author":"Peymani","year":"2016","journal-title":"Acta Biomed"},{"key":"10.1016\/j.cmi.2020.05.016_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1139\/cjpp-2015-0507","article-title":"New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)","volume":"94","author":"Peymani","year":"2016","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.cmi.2020.05.016_bib27","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/jmv.24575","article-title":"Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients","volume":"88","author":"Helal","year":"2016","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2020.05.016_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000785","article-title":"A\u00a0randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults","volume":"4","author":"Tricou","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2020.05.016_bib29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0074-02762013000500010","article-title":"Chloroquine use improves dengue-related symptoms","volume":"108","author":"Borges","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.cmi.2020.05.016_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/vbz.2008.0049","article-title":"On chikungunya acute infection and chloroquine treatment","volume":"8","author":"De Lamballerie","year":"2008","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.cmi.2020.05.016_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187152609787847712","article-title":"Antiviral treatment of chikungunya virus infection","volume":"9","author":"de Lamballerie","year":"2009","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.cmi.2020.05.016_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/v10050268","article-title":"Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection","volume":"10","author":"Roques","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2020.05.016_bib33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10067-016-3429-0","article-title":"Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study","volume":"36","author":"Ravindran","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cmi.2020.05.016_bib34","first-page":"185","article-title":"Multicenter collaboration group of department of science technology of Guangdong Province health commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia","volume":"43","author":"Zhonghua","year":"2020","journal-title":"Expert Consensus Chloroquine Phosphate Treat Novel Coronavirus Pneumonia"},{"key":"10.1016\/j.cmi.2020.05.016_bib35","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2020.05.016_bib36","article-title":"A\u00a0pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Chen Jun","year":"2020","journal-title":"J\u00a0Zhejian Univ"},{"key":"10.1016\/j.cmi.2020.05.016_bib37","article-title":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial","volume":"2020","author":"Tang","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.05.016_bib38","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","volume":"2020","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.05.016_bib39","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19","volume":"2020","author":"Magagnoli","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.05.016_bib40","article-title":"Treating COVID-19 with chloroquine","author":"Huang","year":"2020","journal-title":"J\u00a0Mol Cell Biol"},{"key":"10.1016\/j.cmi.2020.05.016_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2020.05.016_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs)\u2014a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol Ther"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:24:42Z","timestamp":1761117882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20302937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1198743X20302937"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.05.016","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}